Atea Pharmaceuticals Shares Promising Data From Therapy Study For Hepatitis C Virus
Atea Pharmaceuticals announces 97% SVR12 in Phase 2 HCV study of bemnifosbuvir. Data shows high efficacy, safety, and low resistance risk.
SCHOTT Pharma And KORU Medical Systems Announce Collaboration To Advance Large Volume Subcutaneous Infusion
The companies, KORU Medical, manufacturer of the proprietary, large-volume, Freedom Infusion System (the "Freedom System") and SCHOTT Pharma, manufacturer of SCHOTT TOPPAC® prefillable polymer syringes (PFS), intend
IMCC Reports Accelerated Growth In Germany Through New Supply Agreement With EU-GMP Certified Glasshouse Botanics
IMC Germany's accelerated growth potential leans strongly on its supply strategy through its ability to partner with cannabis growers for EU-GMP certification, bolstering the company's supply chain with exclusive
Nanox Launches AI Functionality In Second Opinions Online Medical Consultation Service
Nanox integrates FDA-cleared population health AI solutions into its Second Opinions service New AI capabilities available to patients who submit chest and abdominal CT scans for second opinionsOffering the power
Amneal Expands Broad Injectables Portfolio With The Addition of Six New Product Launches
Amneal's Q2 2024 injectable product launches: Product launchDosage formASHP drug shortage1PEMRYDI RTU®VialNo2Atropine sulfatePrefilled syringeYes3DocetaxelInjectionYes4FoscarnetIV bagNo5Methylprednisolone
Arcutis Reports Multiple Abstracts, Including Oral Presentation At The Revolutionizing Alopecia Areata, Vitiligo, And Eczema Conference From June 8-10, 2024
New long-term safety and efficacy data of investigational roflumilast cream 0.15% in mild to moderate atopic dermatitis will be presented in an oral session Preclinical data on ARQ-234, CD200R agonist, for the
EXCLUSIVE: Adial Pharmaceuticals Starts Patient Dosing In Pharmacokinetics Study Of AD04 For Alcohol Use Disorder
Adial Pharmaceuticals starts dosing in pharmacokinetics study of AD04 for Alcohol Use Disorder in heavy drinking patients. Topline results in early Q4 2024.
MangoRx Gets Patent Notice Of Allowance In Japan For Revolutionary Preventive Care Technology
Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a company focused on developing, marketing, and selling a variety of men's health and wellness products in the area of erectile dysfunction (ED), hair
National Institutes of Health Kickstarts Gilead Sponsored Trials For Twice-Yearly HIV Prevention Injection
The US National Institutes of Health has launched two clinical trials to test a new long-acting form of HIV PrEP in cisgender women and people who inject drugs. These mid-stage studies will evaluate the safety and pharmacokinetics of lenacapavir, a bi-annual injectable antiretroviral drug.
BridgeBio Pharma Shares One Year Data From Dwarfism Candidate
BridgeBio Pharma revealed results from the PROPEL 2 Phase 2 trial of infigratinib in children with achondroplasia. Key data shows sustained increases in height velocity and improved body proportionality with a good safety profile.